Stockscreener 앱 받기
46.47
0.87%
0.40
시간 외 거래:
46.75
0.28
+0.60%
전일 마감가:
$46.07
열려 있는:
$45.98
하루 거래량:
2.55M
Relative Volume:
1.14
시가총액:
$5.98B
수익:
$10.12M
순이익/손실:
$-280.49M
주가수익비율:
-16.08
EPS:
-2.89
순현금흐름:
$-188.51M
1주 성능:
+0.39%
1개월 성능:
+46.59%
6개월 성능:
+43.83%
1년 성능:
+2.15%
1일 변동 폭
$45.32
$47.50
1주일 범위
$43.50
$47.50
52주 변동 폭
$21.51
$56.00
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Avidity Biosciences Inc
전화
858-401-7900
주소
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
46.47 | 5.93B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Bernstein | Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-06-11 | 개시 | Raymond James | Strong Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
Avidity Biosciences (RNA) CHRO McCarthy sells $465k in stock - Investing.com
Avidity Biosciences Executives Sell Shares Under Trading Plans - TradingView
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium - MSN
Avidity Biosciences’ SWOT analysis: RNA stock poised for growth in rare muscle disease market - Investing.com
Avidity Biosciences Inc. Moves Into Overbought Range Analysts CautiousTrend Analysis for Safer Trades Gains Popularity - 선데이타임즈
Avidity Biosciences RNA 2025Q2 Earnings Preview Upside Potential on Novartis Acquisition Talks - AInvest
Avidity Biosciences' Promising Pipeline: Buy Rating Maintained by Ananda Ghosh - AInvest
Avidity Biosciences Bets Big On Rare Disease Therapies - Finimize
Avidity Biosciences Q2 Results: Analysts Boost Revenue Forecasts, Raise Loss Per Share Estimates - AInvest
The Avidity Biosciences, Inc. (NASDAQ:RNA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal - MSN
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $60 to $78 - 富途牛牛
Avidity (RNA) Gets 26% Jump on Potential Takeover - MSN
Avidity Biosciences price target raised to $75 from $70 at Wells Fargo - MSN
Chardan Capital Maintains "Buy" Rating for Avidity Biosciences with $75 Price Target - AInvest
Insider Selling at Avidity Biosciences: A Signal of Routine Tax Obligations or a Cause for Concern? - AInvest
Avidity Biosciences Insider Selling: Signal or Noise in a High-Potential Biotech Play? - AInvest
Avidity Biosciences Shares Slide 2.59% as 230M-Dollar Volume Ranks 431st Amid Analyst Optimism and Deepening Losses - AInvest
Avidity Biosciences Signs Manufacturing Agreement with Lonza - The Globe and Mail
Avidity Biosciences Insider Trading: Officers Buy and Sell Shares on 2025-08-06 - AInvest
Novartis weighs deal for biotech Avidity Biosciences, FT reports - AOL.com
Avidity Biosciences: Strong Buy Rating Backed by Promising Clinical Outcomes and Robust Financial Position - TipRanks
Avidity Biosciences: Wells Fargo maintains a 'Overweight' Rating, The Target Price is $75 - AInvest
Avidity Biosciences: Barclays Keeps Overweight Rating, Raises PT to $62 - AInvest
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $62 - 富途牛牛
Avidity Biosciences: Chardan Capital Maintains Buy, Raises PT to $75 - AInvest
Avidity Biosciences 2025 Q2 Earnings Significant Loss Widening Despite Revenue Surge - AInvest
Avidity (RNA) Q2 Revenue Jumps 88% - AOL.com
Avidity Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Avidity Biosciences Reports Q2 2025 Financial Results and Key Milestones, with Strong Cash Position and Upcoming FDA Submissions - AInvest
Avidity Biosciences: Promising Pipeline and Strategic Developments Drive Buy Rating Amid Potential Novartis Takeover Interest - AInvest
Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c) - TipRanks
Earnings Flash (RNA) Avidity Biosciences, Inc. Reports Q2 Revenue $3.8M - MarketScreener
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights – Company Announcement - Financial Times
Avidity Bio Climbs on Report of Novartis Takeover - MSN
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights07.08.25News - Ariva
Novartis eyes Avidity Biosciences in potential takeover: Report - Medical Dialogues
Rumour mill says Novartis may want to buy Avidity - pharmaphorum
Novartis's Strategic Pursuit of Avidity Biosciences: A Catalyst for Biotech Value and Long-Term Growth? - AInvest
Avidity Biosciences Surges 26% on 877% Volume Spike to 121st Most Traded as High-Volume Stocks Outperform with 166% Returns - AInvest
Novartis Eyes Avidity Biosciences Acquisition to Boost Rare Disease Pipeline - AInvest
Avidity Shares Surge 20% Following Report of Buyout Interest - AInvest
Avidity's Stock Jumps 3% Following Takeover Approach Report - AInvest
Avidity Biosciences Shares Surge Amid Novartis Acquisition Talks - AInvest
Novartis Makes Takeover Bid for Avidity Biosciences with $4.3B Market Value - AInvest
- Yahoo Finance
Biote Corp. shares fall 13.21% after-hours as Novartis considers Avidity Biosciences acquisition. - AInvest
Avidity Biosciences: What’s Fueling its Surge? - timothysykes.com
Small Biotech Catapults On Rumored Novartis Takeover - Investor's Business Daily
Biote Corp. shares fall 6.74% after-hours as Novartis considers Avidity Biosciences acquisition. - AInvest
Avidity Biosciences shares rise 24.05% intraday as Novartis considers a potential takeover offer. - AInvest
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):